A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D
Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-04-15-2014
Volume 2014 eBook
Issue 1
A study investigated the influence and correlation of critical process parameters for the optimization of in-process curing.
Previous studies with EUDRAGIT NM 30 D showed that storage stability can be achieved with in-process curing at specific conditions. The aim of this study was to identify and investigate the influence and correlation of critical process parameters for the optimization of in-process curing.
Download
Pharmaceutical Technology’s 2014 Solid Dosage and Excipients eBook.
Articles in this issue
Safety by Design—Mitigating the Risk of Medication Errors Through Product Design
Controlled-Release Technologies Create Opportunities for Solid-Dosage Drug Formulators
Continuous Manufacturing for Solid-Dosage Drug Production
A Practical Guide to Hot-Melt Extrusion Scale-Up for Pharmaceutical Applications
Using Modular Systems in Solid-Dosage Manufacturing
Advances in Hot-Melt Extrusion Manufacturing
Obtaining User-Defined Particle Size Distribution Using Dry Granulation
A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D
Selection of Excipients in Generic Formulations
Recent Videos
Related Content
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Article
Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
